NO20020467L - Purinderivatinhibitorer av tyrosinproteinkinase syk - Google Patents

Purinderivatinhibitorer av tyrosinproteinkinase syk

Info

Publication number: NO20020467L
Authority: NO; Norway
Prior art keywords: ill; protein kinase; purine derivative; tyrosine protein; derivative inhibitors
Prior art date: 1999-07-30

Application number

NO20020467A

Other languages

English (en)

Norwegian (no)

Other versions

NO20020467D0 (no

Inventor

Stephen Paul Collingwood

Judy Hayler

Darren Mark Le Grand

Henri Mattes

Keith Allan Menear

Clive Victor Walker

Xiao-Ling Cockcroft

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-30

Filing date

2002-01-29

Publication date

2002-03-20

2002-01-29 Application filed by Novartis Ag filed Critical Novartis Ag

2002-01-29 Publication of NO20020467D0 publication Critical patent/NO20020467D0/no

2002-03-20 Publication of NO20020467L publication Critical patent/NO20020467L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

NO20020467A 1999-07-30 2002-01-29 Purinderivatinhibitorer av tyrosinproteinkinase syk NO20020467L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9918035.8A GB9918035D0 (en)	1999-07-30	1999-07-30	Organic compounds
PCT/EP2000/007311 WO2001009134A1 (fr)	1999-07-30	2000-07-28	Inhibiteurs de derives de purine de la tyrosine kinase syk

Publications (2)

Publication Number	Publication Date
NO20020467D0 NO20020467D0 (no)	2002-01-29
NO20020467L true NO20020467L (no)	2002-03-20

Family

ID=10858317

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020467A NO20020467L (no)	1999-07-30	2002-01-29	Purinderivatinhibitorer av tyrosinproteinkinase syk

Country Status (33)

Country	Link
US (1)	US6589950B1 (fr)
EP (1)	EP1200435B1 (fr)
JP (2)	JP2003506375A (fr)
KR (1)	KR100485289B1 (fr)
CN (1)	CN1213047C (fr)
AR (1)	AR029175A1 (fr)
AT (1)	ATE251160T1 (fr)
AU (1)	AU767349B2 (fr)
BR (1)	BR0012888A (fr)
CA (1)	CA2379560C (fr)
CO (1)	CO5180626A1 (fr)
CZ (1)	CZ2002299A3 (fr)
DE (1)	DE60005684T2 (fr)
DK (1)	DK1200435T3 (fr)
EC (1)	ECSP003589A (fr)
ES (1)	ES2208395T3 (fr)
GB (1)	GB9918035D0 (fr)
HK (1)	HK1046679A1 (fr)
HU (1)	HUP0201935A3 (fr)
IL (1)	IL147455A0 (fr)
MX (1)	MXPA02001102A (fr)
MY (1)	MY126862A (fr)
NO (1)	NO20020467L (fr)
NZ (1)	NZ516667A (fr)
PE (1)	PE20010543A1 (fr)
PL (1)	PL354477A1 (fr)
PT (1)	PT1200435E (fr)
RU (1)	RU2248977C2 (fr)
SK (1)	SK285730B6 (fr)
TR (1)	TR200200234T2 (fr)
TW (2)	TWI255268B (fr)
WO (1)	WO2001009134A1 (fr)
ZA (1)	ZA200200783B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001040800A2 (fr) *	1999-11-30	2001-06-07	Parker Hughes Institute	Syk localise au niveau du centrosome
FR2802091A1 (fr) *	1999-12-08	2001-06-15	Oreal	Compositions pour la teinture des fibres keratiniques contenant des derives de paraphenylenediamine a groupement azetidinyle
BR0114020A (pt)	2000-09-20	2003-07-22	Merck Patent Gmbh	4-amino-quinazolinas
ES2556946T3 (es)	2000-12-21	2016-01-21	Novartis Ag	Pirimidinaminas como moduladores de la angiogénesis
GB0101686D0 (en) *	2001-01-23	2001-03-07	Cancer Res Campaign Tech	Cyclin dependent kinase inhibitors
US7829566B2 (en)	2001-09-17	2010-11-09	Werner Mederski	4-amino-quinazolines
CA2463563A1 (fr) *	2001-10-12	2003-04-17	Irm Llc	Squelettes d'inhibiteurs de kinase et leurs methodes de preparation
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
EP1465900B1 (fr)	2002-01-10	2008-05-14	Bayer HealthCare AG	Inhibiteurs de la rho-kinase
ATE381557T1 (de)	2002-01-23	2008-01-15	Bayer Pharmaceuticals Corp	Rho-kinase inhibitoren
US6924290B2 (en)	2002-01-23	2005-08-02	Bayer Pharmaceuticals Corporation	Rho-kinase inhibitors
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
AU2003218736B2 (en)	2002-03-13	2009-01-08	Janssen Pharmaceutica N.V.	New inhibitors of histone deacetylase
US7767679B2 (en)	2002-03-13	2010-08-03	Janssen Pharmaceutica N.V.	Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US6897307B2 (en)	2002-03-28	2005-05-24	Novartis Ag	Process for preparing 2,6-diaminopurine derivatives
US6855724B2 (en)	2002-04-08	2005-02-15	Agouron Pharmaceuticals, Inc.	Tropane derivatives useful in therapy
IL165286A0 (en) *	2002-06-17	2005-12-18	Smithkline Beecham Corp	Chemical process
JP2006502995A (ja) *	2002-07-19	2006-01-26	メモリー・ファーマシューティカルズ・コーポレイション	ホスホジエステラーゼ４阻害剤としての６−アミノ−１ｈ−インダゾール及び４−アミノベンゾフラン化合物
MXPA05001096A (es)	2002-07-29	2005-11-23	Rigel Pharmaceuticals Inc	Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
EP1444982A1 (fr) *	2003-02-06	2004-08-11	Merckle Gmbh	Utilisation des dérivés de purine comme inhibiteurs sélectifs de kinases
AU2004265288A1 (en)	2003-07-30	2005-02-24	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
SG145748A1 (en) *	2003-08-15	2008-09-29	Irm Llc	6-substituted anilino purines as rtk inhibitors
EA009734B1 (ru) *	2003-09-25	2008-02-28	Янссен Фармацевтика Н.В.	Производные пурина, ингибирующие репликацию вич
US20070270448A1 (en) *	2003-11-06	2007-11-22	Celgene Corporation	Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders
US7592177B2 (en) *	2003-11-10	2009-09-22	The Scripps Research Institute	Compositions and methods for inducing cell dedifferentiation
GB0407723D0 (en) *	2004-04-05	2004-05-12	Novartis Ag	Organic compounds
US8057815B2 (en) *	2004-04-19	2011-11-15	Portola Pharmaceuticals, Inc.	Methods of treatment with Syk inhibitors
WO2005118543A1 (fr) *	2004-06-03	2005-12-15	Ono Pharmaceutical Co., Ltd.	Inhibiteur des kinases et utilisation de cet inhibiteur
US20050288290A1 (en) *	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7361763B2 (en)	2004-07-27	2008-04-22	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
US7709645B2 (en) *	2004-07-27	2010-05-04	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
WO2006015124A2 (fr)	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Modulateurs heterocycliques a cycles fusionnes pour les kinases
US7626021B2 (en) *	2004-07-27	2009-12-01	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
US7361764B2 (en) *	2004-07-27	2008-04-22	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
KR101261305B1 (ko)	2004-07-28	2013-05-08	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
US20080027034A1 (en) *	2004-09-10	2008-01-31	Shah Tushar P	Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
US7557207B2 (en)	2004-11-24	2009-07-07	Rigel Pharmaceuticals, Inc.	Spiro 2,4-pyrimidinediamine compounds and their uses
CN100526315C (zh) *	2005-06-16	2009-08-12	浙江医药股份有限公司新昌制药厂	N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
CA2625109A1 (fr) *	2005-10-13	2007-04-19	Glaxo Group Limited	Derives de la pyrrolopyrimidine inhibiteurs de la syk
CA2628474A1 (fr) *	2005-11-03	2007-05-10	Sgx Pharmaceuticals, Inc.	Modulateurs de kinase de type pyrimidinylthiophene
US7601713B2 (en)	2005-12-15	2009-10-13	Rigel Pharmaceuticals, Inc.	Kinase inhibitors and their uses
CA2635015C (fr) *	2006-01-19	2014-06-03	Janssen Pharmaceutica N.V.	Derive d'indolyl-alkyl-amino substitues en tant qu'inhibiteurs d'histone desacetylase
CN101370790B (zh)	2006-01-19	2015-10-21	詹森药业有限公司	作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
HRP20090459T1 (hr) *	2006-01-19	2009-09-30	Janssen Pharmaceutica N.V.	Aminofenil derivati kao novi inhibitori histonskih deacetilaza
EP2001480A4 (fr) *	2006-03-31	2011-06-15	Abbott Lab	Composés d'indazole
EA200970403A1 (ru)	2006-10-23	2009-10-30	ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК.	Бициклические триазолы в качестве модуляторов протеинкиназы
US20080139531A1 (en) *	2006-12-04	2008-06-12	Alcon Manufacturing Ltd.	Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
CN103641833A (zh) *	2006-12-08	2014-03-19	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
HRP20141260T1 (xx)	2006-12-08	2015-03-13	Irm Llc	Spojevi i sastavi kao inhibitori kinaze proteina
RU2009128982A (ru) *	2006-12-28	2011-02-10	Тайсо Фармасьютикал Ко., Лтд. (Jp)	Пиразолопиримидиновые соединения
US8404674B2 (en)	2007-03-07	2013-03-26	Boehringer Ingelheim International Gmbh	Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
MX2009010984A (es)	2007-04-10	2010-01-15	Sgx Pharmaceuticals Inc	Moduladores de heterociclo cinasa de anillo fusionado.
CN101289449A (zh) *	2007-04-20	2008-10-22	浙江医药股份有限公司新昌制药厂	2,6-二含氮取代的嘌呤衍生物及其制备方法和应用
WO2008135232A1 (fr) *	2007-05-02	2008-11-13	Riccardo Cortese	Utilisation et compositions de dérivés de purine pour le traitement de troubles prolifératifs
AU2008254588B2 (en) *	2007-05-21	2013-01-17	Sgx Pharmaceuticals, Inc.	Heterocyclic kinase modulators
TW200908968A (en) *	2007-05-29	2009-03-01	Sgx Pharmaceuticals Inc	Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
US7705004B2 (en)	2007-08-17	2010-04-27	Portola Pharmaceuticals, Inc.	Protein kinase inhibitors
FR2929851B1 (fr)	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
AU2009244897B2 (en)	2008-04-16	2014-11-13	Alexion Pharmaceuticals, Inc.	2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
EP2271631B1 (fr) *	2008-04-22	2018-07-04	Portola Pharmaceuticals, Inc.	Inhibiteurs de protéines kinases
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
EA029131B1 (ru)	2008-05-21	2018-02-28	Ариад Фармасьютикалз, Инк.	Фосфорсодержащие производные в качестве ингибиторов киназы
US20100029689A1 (en) *	2008-07-02	2010-02-04	Memory Pharmaceuticals Corporation	Phosphodiesterase 4 inhibitors
WO2010111406A2 (fr) *	2009-03-24	2010-09-30	Myriad Pharmaceuticals, Inc.	Composés et leurs utilisations thérapeutiques
ES2609040T3 (es) *	2009-12-17	2017-04-18	Merck Sharp & Dohme Corp.	Aminopirimidinas como inhibidores de Syk
PT2516434E (pt)	2009-12-23	2015-10-05	Takeda Pharmaceutical	Pirrolidinonas heteroaromáticas fundidas como inibidores de syk
WO2011153553A2 (fr)	2010-06-04	2011-12-08	The Regents Of The University Of California	Méthodes et compositions pour l'inhibition de kinases
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
EA201391626A1 (ru)	2011-05-04	2014-03-31	Ариад Фармасьютикалз, Инк.	Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
US9120785B2 (en)	2011-05-10	2015-09-01	Merck Sharp & Dohme Corp.	Pyridyl aminopyridines as Syk inhibitors
US9290490B2 (en)	2011-05-10	2016-03-22	Merck Sharp & Dohme Corp.	Aminopyrimidines as Syk inhibitors
EP2706852B1 (fr)	2011-05-10	2018-08-22	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines en tant qu'inhibiteurs de syk
EP2713737B1 (fr)	2011-06-01	2016-04-20	Janus Biotherapeutics, Inc.	Nouveaux modulateurs du système immunitaire
EP2723739B1 (fr)	2011-06-22	2016-08-24	Takeda Pharmaceutical Company Limited	Dérivés de 6-aza-isoindolin-1-one substitués
WO2013052393A1 (fr)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
WO2013052391A1 (fr)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
US9216173B2 (en)	2011-10-05	2015-12-22	Merck Sharp & Dohme Corp.	2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
JP6039683B2 (ja)	2011-11-23	2016-12-07	ポートラファーマシューティカルズ，インコーポレイテッド	ピラジンキナーゼ阻害剤
AR090650A1 (es) *	2012-04-12	2014-11-26	Alcon Res Ltd	Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2013192128A1 (fr)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Analogues d'imidazolyle en tant qu'inhibiteurs de syk
WO2013192125A1 (fr)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
EP2863915B1 (fr)	2012-06-22	2017-12-06	Merck Sharp & Dohme Corp.	Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
EP2863916B1 (fr)	2012-06-22	2018-07-18	Merck Sharp & Dohme Corp.	Inhibiteurs à pyridine substituée de la tyrosine kinase de la rate (syk)
WO2014031438A2 (fr)	2012-08-20	2014-02-27	Merck Sharp & Dohme Corp.	Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
US9586931B2 (en)	2012-09-28	2017-03-07	Merck Sharp & Dohme Corp.	Triazolyl derivatives as Syk inhibitors
US9624210B2 (en)	2012-12-12	2017-04-18	Merck Sharp & Dohme Corp.	Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2934525B1 (fr)	2012-12-21	2019-05-08	Merck Sharp & Dohme Corp.	Aminopyridines substituées par thiazole en tant qu'inhibiteurs de la tyrosine kinase de la rate
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014176210A1 (fr)	2013-04-26	2014-10-30	Merck Sharp & Dohme Corp.	Composés aminohétéroaryle à substitution thiazole inhibiteurs de tyrosine kinase splénique
WO2014176216A1 (fr)	2013-04-26	2014-10-30	Merck Sharp & Dohme Corp.	Aminopyrimidines substituées par thiazole utilisées en tant qu'inhibiteurs de tyrosine kinase splénique
CN104418858B (zh) *	2013-08-30	2018-12-11	浙江医药股份有限公司新昌制药厂	2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
US9783531B2 (en)	2013-12-20	2017-10-10	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (fr)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
EP3083560B1 (fr)	2013-12-20	2021-10-27	Merck Sharp & Dohme Corp.	Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
US9775839B2 (en)	2014-03-13	2017-10-03	Merck Sharp & Dohme Corp.	2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2015162518A1 (fr)	2014-04-25	2015-10-29	Pfizer Inc.	Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
RU2570113C1 (ru) *	2014-12-08	2015-12-10	Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук	N-(2-ацетамидопурин-6-ил)глицин, обладающий противотуберкулезной активностью
EP3778604B1 (fr) *	2015-02-13	2026-01-07	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EP3324950B1 (fr) *	2015-07-24	2020-01-15	Glaxo Group Limited	Traitement du vitiligo
US10711002B2 (en)	2016-04-21	2020-07-14	The Royal Institution For The Advancement Of Learning/Mcgill University	Purine compounds and method for the treatment of cancer
EP3528816A4 (fr) *	2016-10-21	2020-04-08	Nimbus Lakshmi, Inc.	Inhibiteurs de tyk2 et leurs utilisations
AU2018350683A1 (en)	2017-10-19	2020-04-02	Bayer Animal Health Gmbh	Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019241896A1 (fr) *	2018-06-22	2019-12-26	The Royal Institution For The Advancement Of Learning/Mcgill University	Composés de purine et procédé pour letraitement du cancer
US12098117B2 (en)	2018-12-11	2024-09-24	Duke University	Compositions and methods for the treatment of cancer
EP3942045A1 (fr)	2019-03-21	2022-01-26	Onxeo	Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3529497A1 (de)	1985-08-17	1987-02-26	Boehringer Mannheim Gmbh	N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
FI943798A7 (fi)	1992-02-19	1994-08-18	Pfizer	Kasvaimenvastaisen vaikutuksen lisäämiseen tarkoitettuja heterosyklisi ä yhdisteitä
WO1993020078A1 (fr) *	1992-04-03	1993-10-14	The Upjohn Company	Amines bicycliques-heterocycliques efficaces pharmaceutiquement
US5550132A (en)	1994-06-22	1996-08-27	University Of North Carolina	Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
GB9417249D0 (en) *	1994-08-26	1994-10-19	Wellcome Found	A novel salt
ES2196181T3 (es) *	1995-11-01	2003-12-16	Novartis Ag	Derivados de purina y proceso para su preparacion.
US5866702A (en) *	1996-08-02	1999-02-02	Cv Therapeutics, Incorporation	Purine inhibitors of cyclin dependent kinase 2
AU735127B2 (en)	1997-08-07	2001-06-28	Regents Of The University Of California, The	Purine inhibitor of protein kinases, G proteins and polymerases
GB9903762D0 (en) *	1999-02-18	1999-04-14	Novartis Ag	Organic compounds

1999
- 1999-07-30 GB GBGB9918035.8A patent/GB9918035D0/en not_active Ceased
2000
- 2000-07-20 TW TW089114515A patent/TWI255268B/zh not_active IP Right Cessation
- 2000-07-20 TW TW94101835A patent/TWI274754B/zh not_active IP Right Cessation
- 2000-07-25 PE PE2000000744A patent/PE20010543A1/es not_active Application Discontinuation
- 2000-07-26 CO CO00056110A patent/CO5180626A1/es not_active Application Discontinuation
- 2000-07-27 EC EC2000003589A patent/ECSP003589A/es unknown
- 2000-07-27 AR ARP000103890A patent/AR029175A1/es unknown
- 2000-07-28 MX MXPA02001102A patent/MXPA02001102A/es active IP Right Grant
- 2000-07-28 AT AT00953112T patent/ATE251160T1/de not_active IP Right Cessation
- 2000-07-28 CZ CZ2002299A patent/CZ2002299A3/cs unknown
- 2000-07-28 PT PT00953112T patent/PT1200435E/pt unknown
- 2000-07-28 BR BR0012888-0A patent/BR0012888A/pt not_active Application Discontinuation
- 2000-07-28 MY MYPI20003444 patent/MY126862A/en unknown
- 2000-07-28 SK SK126-2002A patent/SK285730B6/sk not_active IP Right Cessation
- 2000-07-28 RU RU2002103305/04A patent/RU2248977C2/ru not_active IP Right Cessation
- 2000-07-28 AU AU65677/00A patent/AU767349B2/en not_active Ceased
- 2000-07-28 TR TR2002/00234T patent/TR200200234T2/xx unknown
- 2000-07-28 EP EP00953112A patent/EP1200435B1/fr not_active Expired - Lifetime
- 2000-07-28 KR KR10-2002-7001276A patent/KR100485289B1/ko not_active Expired - Fee Related
- 2000-07-28 ES ES00953112T patent/ES2208395T3/es not_active Expired - Lifetime
- 2000-07-28 CA CA002379560A patent/CA2379560C/fr not_active Expired - Fee Related
- 2000-07-28 IL IL14745500A patent/IL147455A0/xx unknown
- 2000-07-28 DK DK00953112T patent/DK1200435T3/da active
- 2000-07-28 WO PCT/EP2000/007311 patent/WO2001009134A1/fr not_active Ceased
- 2000-07-28 PL PL00354477A patent/PL354477A1/xx not_active Application Discontinuation
- 2000-07-28 NZ NZ516667A patent/NZ516667A/en unknown
- 2000-07-28 HU HU0201935A patent/HUP0201935A3/hu unknown
- 2000-07-28 HK HK02107013.6A patent/HK1046679A1/zh unknown
- 2000-07-28 JP JP2001514337A patent/JP2003506375A/ja not_active Withdrawn
- 2000-07-28 US US10/048,577 patent/US6589950B1/en not_active Expired - Lifetime
- 2000-07-28 DE DE60005684T patent/DE60005684T2/de not_active Expired - Fee Related
- 2000-07-28 CN CNB008110263A patent/CN1213047C/zh not_active Expired - Fee Related
2002
- 2002-01-29 NO NO20020467A patent/NO20020467L/no not_active Application Discontinuation
- 2002-01-29 ZA ZA200200783A patent/ZA200200783B/en unknown
2007
- 2007-05-16 JP JP2007130684A patent/JP2007217426A/ja active Pending

Also Published As

Publication number	Publication date
GB9918035D0 (en)	1999-09-29
BR0012888A (pt)	2002-04-09
HUP0201935A2 (hu)	2002-11-28
HK1046679A1 (zh)	2003-01-24
TWI274754B (en)	2007-03-01
JP2007217426A (ja)	2007-08-30
US6589950B1 (en)	2003-07-08
MY126862A (en)	2006-10-31
PT1200435E (pt)	2004-02-27
EP1200435B1 (fr)	2003-10-01
WO2001009134A1 (fr)	2001-02-08
SK285730B6 (sk)	2007-07-06
AU767349B2 (en)	2003-11-06
CN1365360A (zh)	2002-08-21
NO20020467D0 (no)	2002-01-29
AU6567700A (en)	2001-02-19
CA2379560A1 (fr)	2001-02-08
CO5180626A1 (es)	2002-07-30
CZ2002299A3 (cs)	2002-04-17
ZA200200783B (en)	2003-04-30
MXPA02001102A (es)	2002-08-20
KR20020015394A (ko)	2002-02-27
ATE251160T1 (de)	2003-10-15
DE60005684T2 (de)	2004-07-29
TR200200234T2 (tr)	2002-06-21
IL147455A0 (en)	2002-08-14
DK1200435T3 (da)	2004-02-02
JP2003506375A (ja)	2003-02-18
DE60005684D1 (de)	2003-11-06
CA2379560C (fr)	2009-09-29
ECSP003589A (es)	2002-02-25
KR100485289B1 (ko)	2005-04-27
NZ516667A (en)	2004-05-28
ES2208395T3 (es)	2004-06-16
RU2248977C2 (ru)	2005-03-27
PL354477A1 (en)	2004-01-26
PE20010543A1 (es)	2001-05-14
SK1262002A3 (en)	2002-07-02
TW200524932A (en)	2005-08-01
CN1213047C (zh)	2005-08-03
EP1200435A1 (fr)	2002-05-02
TWI255268B (en)	2006-05-21
AR029175A1 (es)	2003-06-18
HUP0201935A3 (en)	2005-02-28

Publication	Publication Date	Title
NO20020467L (no)	2002-03-20	Purinderivatinhibitorer av tyrosinproteinkinase syk
CY2008015I1 (el)	2009-11-04	Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
FR13C0003I2 (fr)	2015-11-20	Inhibiteurs cycliques de proteine tyrosine kinase
ATE445613T1 (de)	2009-10-15	Indolylmaleimidderivative als proteinkinase-c- inhibitoren
CY2014034I1 (el)	2016-04-13	Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
NO20021820D0 (no)	2002-04-18	Tyrosinkinaseinhibitorer
EP1161433A4 (fr)	2002-05-08	Inhibiteurs de tyrosine kinase
ATE255575T1 (de)	2003-12-15	Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
NO20022864L (no)	2002-08-13	Aminotiazol inhibitorer av syklin uavhengig kinase
ATE430149T1 (de)	2009-05-15	Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
DE60117568D1 (de)	2006-04-27	Kondensierte pyrazol derivate als protein kinase inhibitoren
NO20021783D0 (no)	2002-04-16	Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase
DE69511253D1 (de)	1999-09-09	Wasserlösliche 3-arylidene-2-oxindole derivate als tyrosine kinase inhibitoren
NO990123D0 (no)	1999-01-12	Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
NO990124D0 (no)	1999-01-12	Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
ATE205836T1 (de)	2001-10-15	Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren

Legal Events

Date	Code	Title	Description
2010-02-15	FC2A	Withdrawal, rejection or dismissal of laid open patent application